ATC Code: N06 AG 02
Pharmacotherapeutic group: antidepressant
Manerix is an antidepressant which affects the monoaminergic cerebral neurotransmitter system by means of a reversible inhibition of monoamine oxidase preferentially of type A (RIMA). The metabolism of noradrenaline, dopamine and serotonin (5-HT) is decreased by this effect, and this leads to increased extracellular concentrations of these neuronal transmitters.
As a result of its elevating effect on mood and psychomotor activity, Manerix relieves symptoms such as dysphoria, exhaustion, lack of drive and inability to concentrate.
These effects most often appear within the first week of therapy. Manerix also relieves symptoms related to social phobia.
Though Manerix has no sedative properties, it improves the quality of sleep in most depressive patients within days. Manerix does not impair alertness.
Short-term and long-term animal studies indicate low toxicity. No cardiac toxicity has been observed.
